AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35810555
Drug: Standard anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticancer therapies
Trial: 35812817
Drug: Elobixibat (EXB)
RxNorm normalized name: Exblifep
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat (EXB) 10 mg/day for 4 weeks
Trial: 35814366
Drug: AHCC 3-g
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHCC 3-g supplementation by mouth once daily on empty stomach for 6 months
Trial: 35814366
Drug: Suppression of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppression of IFN-β to less than 20 pg/ml
Trial: 35815408
Drug: 9-ING-41, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-ING-41, a selective GSK-3β inhibitor
Trial: 35815666
Drug: Standardized feminizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized feminizing hormone therapy (sFHT; oestradiol valerate 2-6 mg plus spironolactone 100-300 mg) plus PrEP for 12 weeks
Trial: 35815666
Drug: Any feminizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any feminizing hormone therapy (aFHT) plus PrEP (long-term PK)
Trial: 35816381
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity program including 3 types of exercises: staying out of bed for at least 3 hours, performing balance exercises while standing for 2 minutes, and the Five Times Sit to Stand transfer exercise.
Trial: 35816381
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity program
Trial: 35816411
Drug: ARCoV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCoV vaccine
Trial: 35816490
Drug: APN01 (soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APN01 (soluble human recombinant ACE2) administered via nebulizer, twice daily for two weeks at maximum feasible concentration
Trial: 35816831
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray (Valtoco®)
Trial: 35816942
Drug: Cyberknife System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyberknife System treatment plans based on unrotated volume
Trial: 35816942
Drug: Cyberknife System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyberknife System treatment plans based on envelope of unrotated and rotated volumes
Trial: 35816942
Drug: Gamma analysis
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma analysis of treatment plans
Trial: 35816951
Drug: Retifanlimab 500
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab 500 mg administered intravenously every 4 weeks
Trial: 35818348
Drug: Oxaliplatin (OX)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (OX) treatment
Trial: 35818888
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management strategies
Trial: 35819130
Drug: Weekly digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly digital follow-up of lung cancer patients
Trial: 35819130
Drug: Weekly digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly digital follow-up of lung cancer patients (pilot study)
Trial: 35819446
Drug: miR-146b-5p mimic
RxNorm normalized name: Pyridoxal-5P
DrugBank: Pyridoxal phosphate (DB00114)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: miR-146b-5p mimic administration to NSG mice engrafted with CLL cells
Trial: 35819446
Drug: Downregulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Downregulation of miR-146b-5p with specific miRNA inhibitors in vitro
Trial: 35820054
Drug: Opal patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opal patient portal intervention for distance monitoring of self-isolating patients with COVID-19, involving daily self-assessment of symptoms, vital signs, and mental health monitored by a nurse, with teleconsultations as needed.
Trial: 35820718
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion (1×10^6 cells)
Trial: 35820718
Drug: Umbilical cord
RxNorm normalized name: Sus Scrofa Umbilical Cord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord mesenchymal stromal cells (UC MSCs) infusion
Trial: 35820889
Drug: APG-2449 in
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-2449 in combination with paclitaxel
Trial: 35821349
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (GnRH-ant) protocol
Trial: 35821349
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH-a) protocol
Trial: 35821380
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) treatment intervals of < 8 weeks
Trial: 35821380
Drug: Non-injection-intensive patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-injection-intensive patients
Trial: 35821806
Drug: Uthever (NMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uthever (NMN Supplement)
Trial: 35821844
Drug: Glycine and
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at low dose (2.4 g/day) for 2 weeks
Trial: 35821844
Drug: Glycine and
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at medium dose (4.8 g/day) for 2 weeks
Trial: 35821844
Drug: Glycine and
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine and N-Acetylcysteine supplementation (GlyNAC) at high dose (7.2 g/day) for 2 weeks
Trial: 35822945
Drug: Average PrEP
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average PrEP dosing
Trial: 35829780
Drug: Rituximab combined
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab combined with intensive chemotherapy (group R1)
Trial: 35829780
Drug: Rituximab combined
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab combined with intensive chemotherapy (group R2)
Trial: 35829780
Drug: Rituximab combined
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab combined with intensive chemotherapy (group R3)
Trial: 35829780
Drug: Rituximab combined
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab combined with intensive chemotherapy (group R4)
Trial: 35830707
Drug: Structured approach
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured approach including daily assessment of readiness to extubate
Trial: 35830841
Drug: Lurbinectedin at
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin at 3.2 mg/m
Trial: 35830931
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) at 1 mg/kg/day, with 11 infusions per cycle of 28 days at a dose of 0.15 mg/kg per infusion.
Trial: 35830931
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) treatment
Trial: 35831040
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment in UAP patients
Trial: 35831783
Drug: MRd (Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRd (Medication Reconciliation at discharge)
Trial: 35832045
Drug: Rehabilitation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation of masticatory function with fixed implant-supported dentures and nutrition education
Trial: 35832177
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg/day after initial dose escalation for up to 60 months
Trial: 35832177
Drug: Ozanimod 0.92
RxNorm normalized name: ozanimod 0.92 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 0.92 mg/day
Trial: 35832286
Drug: Elevated hsCRP
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated hsCRP levels (>3 mg/l) in FM patients
Trial: 35832447
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg intravenously every 2 weeks plus apatinib 250 mg orally once daily
Trial: 35834242
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline remnant-C (≥31 mg/dL)
Trial: 35834242
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline remnant-C in LDL-C subgroup (>100 mg/dL)
Trial: 35834242
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline remnant-C in LDL-C subgroup (≤100 mg/dL)
Trial: 35834598
Drug: Neoadjuvant mFOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant mFOLFOXIRI chemotherapy
Trial: 35835137
Drug: Zandelisib 60
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib 60 mg once daily (intermittent dosing)
Trial: 35835137
Drug: Zandelisib 120
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib 120 mg once daily (intermittent dosing)
Trial: 35835137
Drug: Zandelisib 180
RxNorm normalized name: Zandelisib
DrugBank: Zandelisib (DB18245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib 180 mg once daily (intermittent dosing)
Trial: 35835137
Drug: Zandelisib (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib (intermittent dosing)
Trial: 35835137
Drug: Zandelisib (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib (continuous dosing)
Trial: 35835137
Drug: Zandelisib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib (both dosing schedules)
Trial: 35835491
Drug: SCAI staging
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCAI staging system parameters (hypotension, hypoperfusion, treatment intensity)
Trial: 35835611
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W for 35 cycles
Trial: 35835738
Drug: Antibody-dependent phagocytosis
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-dependent phagocytosis of ring-infected erythrocytes
Trial: 35835738
Drug: Antibody-dependent phagocytosis
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-dependent phagocytosis of uninfected erythrocytes
Trial: 35837200
Drug: Dose-escalated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated proton therapy with elective nodal irradiation (40.5 GyRBE in 18 fractions followed by 22.5 GyRBE boost); Oral capecitabine (1,000 mg twice daily) during treatment
Trial: 35837200
Drug: Dose-escalated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated proton therapy with elective nodal irradiation
Trial: 35837409
Drug: Butantan-DV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butantan-DV vaccine
Trial: 35838207
Drug: Antitumor treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antitumor treatment (surgery, radiotherapy, chemotherapy)
Trial: 35838207
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug (AED) treatment (levetiracetam)
Trial: 35838207
Drug: Benzodiazepines via
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines via nonoral administration routes
Trial: 35838993
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg 1% propofol (group P: n = 30)
Trial: 35838993
Drug: No propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No propofol administration (group C: n = 83)
Trial: 35839426
Drug: Postconsolidation immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2
Trial: 35840573
Drug: Amcenestrant 20-600
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant 20-600 mg QD
Trial: 35840912
Drug: Short-course preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab (4 injections starting on the same day and on weeks 4, 7, and 10)
Trial: 35841307
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy (initial primary surgery in 7 cases)
Trial: 35841307
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (5 patients)
Trial: 35842229
Drug: 1+ incident
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable types
Trial: 35842567
Drug: Trilaciclib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trilaciclib (200 or 240 mg/m)
Trial: 35842567
Drug: Trilaciclib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trilaciclib (200 or 240 mg/m) with rifampin
Trial: 35842567
Drug: Trilaciclib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trilaciclib (200 or 240 mg/m) with itraconazole
Trial: 35843046
Drug: Balanced solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solutions (Plasma Lye 148)
Trial: 35843046
Drug: Balanced solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solutions (Plasma Lye 148) in traumatic brain injury patients
Trial: 35843546
Drug: AB680 (CD73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB680 (CD73 inhibitor)
Trial: 35843546
Drug: palbociclib (CDK4/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palbociclib (CDK4/6 inhibitor)
Trial: 35843546
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AB680 and palbociclib
Trial: 35843739
Drug: Sapanisertib 3
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 3 or 4 mg, Serabelisib 200 mg on days 2-4, 9-11, 16-18 and 23-25 with Paclitaxel 80 mg/m2 on days 1, 8 and 15 every 28 days
Trial: 35844014
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow concentrate (BMC) injections
Trial: 35844168
Drug: OROS-MPH (osmotic-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS-MPH (osmotic-release oral system methylphenidate)
Trial: 35844168
Drug: Omega-3 with
RxNorm normalized name: Omega-3 With CoQ10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 with risperidone and usual anti-seizure medication (ASM)
Trial: 35844773
Drug: Topical ENERGI-F703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ENERGI-F703 gel applied twice daily for 12 weeks or until complete ulcer closure
Trial: 35844773
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel applied twice daily for 12 weeks or until complete ulcer closure
Trial: 35845461
Drug: Socio-demographic, clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Socio-demographic, clinical and biological assessments including blood and hair cortisol levels, plasma pro- and mature BDNF isoforms proportion
Trial: 35845530
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment for LARC
Trial: 35845797
Drug: Multispecies synbiotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multispecies synbiotic supplement (once daily for 12 weeks)
Trial: 35846031
Drug: Avadomide (CC-122)
RxNorm normalized name: Avadomide
DrugBank: Avadomide (DB14857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avadomide (CC-122) 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2
Trial: 35846096
Drug: Oral selinexor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selinexor plus low-dose dexamethasone (Sel-dex)
Trial: 35846096
Drug: Other available
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other available therapies (control group)
Trial: 38415370
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of treatment (PCT)
Trial: 35846221
Drug: CC-122 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-122 plus rituximab
Trial: 35846221
Drug: CC-223 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-223 and CC-292 combinations
Trial: 35846226
Drug: Lebrikizumab 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab 37.5 mg
Trial: 35846272
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hyperaldosteronism
Trial: 35847877
Drug: Gallium68-fibroblast-activation protein
RxNorm normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallium68-fibroblast-activation protein inhibitor
Trial: 35848614
Drug: ISIKOK-19 T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIKOK-19 T-cell therapy
Trial: 35848990
Drug: 1.25% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25% pilocarpine ophthalmic solution eye drops
Trial: 35850782
Drug: XR-NTX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX treatment
Trial: 35852004
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy (Arm D)
Trial: 35852004
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with lenalidomide ± rituximab (Arm A)
Trial: 35852004
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with ibrutinib (Arm B)
Trial: 35852004
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in combination with rituximab ± bendamustine (Arm C)
Trial: 35852004
Drug: Durvalumab (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (monotherapy or combination)
Trial: 35852094
Drug: transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transcranial direct current stimulation (tDCS) at 2 mA for 30 minutes daily for 4 months
Trial: 35852619
Drug: Modified DEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified DEP regimen as induction therapy
Trial: 35852839
Drug: AG-920, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-920, a topical ocular anesthetic
Trial: 35853530
Drug: Omnipod® 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnipod® 5 Automated Insulin Delivery (AID) System
Trial: 35853681
Drug: Testing for
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing for T790M mutation after progression on 1L treatment
Trial: 35853681
Drug: Second-line (2L)
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line (2L) treatment with osimertinib
Trial: 35853994
Drug: ERY974 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERY974 at a starting dose of 3.0 ng/kg
Trial: 35853994
Drug: ERY974 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERY974 at 0.1 μg/kg
Trial: 35854137
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BoNT) injection